Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Newave Pharmaceutical Inc
Newave Pharmaceutical Inc
University of California, San Francisco
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AbbVie
Calithera Biosciences, Inc
National Cancer Institute (NCI)
Millennium Pharmaceuticals, Inc.